Global diagnostic device and service provider Alere has secured the US Food and Drug Administration 510(k) marketing approval for its Alere i RSV Rapid Molecular Test to detect respiratory syncytial virus (RSV) in children and adults.

Alere i RSV is the latest development on the Alere i platform following the Alere i Influenza A & B and Alere i Strep A tests.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Alere infectious disease global president Avi Pelossof said: "Our innovative Alere i platform now allows for the rapid molecular detection of RSV, Influenza A & B and Strep A.

"The availability of clinically meaningful results in an actionable timeframe empowers clinicians to deliver prompt and appropriate patient care."

"The availability of clinically meaningful results in an actionable timeframe empowers clinicians to deliver prompt and appropriate patient care.

“We are excited to continue our ground-breaking innovation on this platform with multiple new analytes progressing well through product development."

See Also:

The molecular test can be used to detect RSV nasopharyngeal within 13 minutes or less by examining swab samples using Alere’s patented Molecular in Minutes isothermal nucleic acid amplification technology (iNAT).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In acute care settings, the simple to use point-of-care RSV test offers speed and molecular accuracy to promote early and appropriate supportive care in order to avoid unnecessary antibiotic treatment.

An early initiation of infection control measures aids in controlling the spread of the highly contagious and malignant virus.

The company is planning to apply for Clinical Laboratory Improvement Amendments (CLIA) waiver of the Alere i RSV test.